Esfahani, Khashayar
Al-Aubodah, Tho-Alfakar
Thebault, Pamela
Lapointe, Réjean
Hudson, Marie
Johnson, Nathalie A.
Baran, Dana
Bhulaiga, Najwa
Takano, Tomoko http://orcid.org/0000-0001-9367-4124
Cailhier, Jean-François
Piccirillo, Ciriaco A.
Miller, Wilson H.
Article History
Received: 16 January 2019
Accepted: 16 September 2019
First Online: 17 October 2019
Competing interests
: Khashayar Esfahani reports receiving speaker’s fees from Bristol-Myers Squibb, outside the submitted work. Wilson Miller reports receiving grants from Bristol-Myers Squibb, Merck, Roche, Novartis, AstraZeneca, Amgen, Bayer, MedImmune and GlaxoSmithKline, outside the submitted work, as well as personal fees from Bristol-Myers Squibb, Merck, Roche, Novartis, Amgen and GlaxoSmithKline. Marie Hudson reports receiving a grant from Bristol-Myers Squibb, outside the submitted work. Nathalie Johnson has received honoraria and consulting fees from Bristol-Myers Squibb and Merck Canada. The remaining authors declare no competing interest.